NMS·Healthcare·$1.4B·#147 / 520 in Healthcare
ABCL AbCellera Biologics Inc.
59SPECULATIVE
CATEGORY BREAKDOWN
GROWTH100
QUALITY32
STABILITY55
VALUATION15
GOVERNANCE86
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+160.6%
100
> 50% strong
Gross Margin
Revenue retained after direct costs
38.4%
53
> 50% strong
Cash Runway
Months of cash at current burn rate
12 months
39
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
14.8%
88
< 25% strong
Price / Sales
Market cap relative to trailing revenue
18.7x
15
< 3x strong
Rule of 40
Growth rate plus operating margin
-110
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
22.6%
89
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+3.2%
81
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE ABCL WITH…
OR QUICK-COMPARE SECTOR PEERS
RELATED RESEARCH
4 Best Small-Cap AI Drug Discovery Stocks — May 2026May 4, 2026SCORE ALERT
Get notified when ABCL's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.